Image-guided percutaneous cryoablation of T1b renal cell carcinomas in patients with comorbidities.

Jpn J Radiol

Department of Radiology, Kashiwa Hospital, The Jikei University School of Medicine, Jikei University, Kashiwashita 163-1, Kashiwa-shi, Chiba, 277-8567, Japan.

Published: December 2021

Purpose: To investigate the influence of comorbidities and tumor characteristics on outcomes following percutaneous cryoablation (PCA) of T1b renal cell carcinoma (RCC).

Materials And Methods: Age-adjusted Charlson comorbidity index (ACCI); standardized system for quantitating renal tumor size, location, and depth (RENAL nephrometry score [RNS]); and local tumor control and survival were retrospectively investigated in 28 patients who underwent PCA for stage T1b RCC. Risk factors for elevated serum creatinine levels were also investigated.

Results: Complete ablation was obtained in 27 of 28 patients. Two cases of metastasis were observed; one patient died 12 months after PCA. Overall survival at 5 years was 79.1%, with a mean follow-up of 42.0 ± 16.0 months. Local tumor control was not correlated with the ACCI and RNS. Worsening renal function 3 months after PCA was observed in ten patients, and it correlated with the presence of single kidneys (7/28 patients; p = 0.023). Significant worsening of renal function continued until 1 year after PCA (p = 0.013). Having a single kidney was a risk factor for worsened renal function after PCA (odds ratio, 8.00; 95% confidence interval 1.170-54.724).

Conclusion: PCA for T1b RCC confers positive local tumor control regardless of comorbidities and tumor characteristics.

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11604-021-01168-8DOI Listing

Publication Analysis

Top Keywords

local tumor
12
tumor control
12
renal function
12
percutaneous cryoablation
8
t1b renal
8
renal cell
8
comorbidities tumor
8
tumor characteristics
8
pca t1b
8
t1b rcc
8

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!